Tempus AI reports 30.4% YoY revenue growth in FY2024, driven by genomics and data services. Discover key metrics and ...

The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing ...

Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms ...

Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Aaron ...

Former House Speaker Nancy Pelosi's stock portfolio has taken a major hit in 2025, aligning with the broader market sell-off.

We will be discontinuing mailing hard copies of patient results to all U.S.-based providers. This change will take effect on April 7, 2025 as part of our efforts to streamline operations and enhance ...

Norges Bank acquired a new position in Tempus AI, Inc. (NASDAQ:TEM – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange ...

We recently published a list of 10 Stocks That Will Profit From AI. In this article, we are going to take a look at where Tempus AI, Inc. (NASDAQ:TEM) stands against other stocks that will profit from ...

In February 2025, Tempus AI, Inc. (NASDAQ:TEM) completed the acquisition of Ambry Genetics, enhancing its capabilities in genetic testing and data services. Tempus’s stock has experienced ...

Deep 6’s advanced algorithms complement Tempus AI’s existing platform, strengthening its foothold in AI-driven healthcare. The February 2025 acquisition of Ambry Genetics further expanded its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...